BDX - Becton Dickinson to market Accelerate Diagnostics' rapid tests for antibiotic resistance

• Becton, Dickinson and Company ( NYSE: BDX ) signed an agreement to offer Accelerate Diagnostics' ( NASDAQ: AXDX ) rapid testing solution for antibiotic resistance and susceptibility.
• Under the agreement, BDX will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits in territories where products have regulatory approval or registration.
• BDX said the test offer results in hours, compared to one to two days with some traditional laboratory methods.
• These solutions complement BDX's existing Clinical Microbiology, the companies said in an Aug. 15 press release.
• "Rapid testing can quickly determine if an antibiotic should be used for treatment, and if so, which one," said Brooke Story, president of Integrated Diagnostic Solutions for BDX.

For further details see: